Viral infections in lung transplant recipients

Seminars in Respiratory and Critical Care Medicine

Volumn 31, Issue 2, 2010, Pages 243-254

  Shah, Pali Dedhiya ^a   McDyer, John F ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Lung transplantation; Respiratory virus

Indexed keywords

ALN RSV 01; AMANTADINE; AMANTADINE PLUS OSELTAMIVIR; ANTIVIRUS AGENT; CORTICOSTEROID; H1N1 INFLUENZA VACCINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; OSELTAMIVIR; PALIVIZUMAB; PARAMYXOVIRUS VACCINE; RIBAVIRIN; RIMANTADINE; RSV 604; UNCLASSIFIED DRUG; VIRUS VACCINE; ZANAMIVIR;

CHRONIC ALLOGRAFT DYSFUNCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LUNG INFECTION; LUNG TRANSPLANTATION; METAPNEUMOVIRUS; MORBIDITY; MORTALITY; NONHUMAN; PARAINFLUENZA VIRUS; PARAMYXOVIRUS; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RHINOVIRUS; RNA VIRUS INFECTION; VIRUS INFECTION;

ANTIVIRAL AGENTS; GRAFT REJECTION; HUMANS; LUNG TRANSPLANTATION; OPPORTUNISTIC INFECTIONS; PROGNOSIS; SURVIVAL ANALYSIS; VIRUS DISEASES;

EID: 77950534954     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0030-1249120     Document Type: Review

References (111)

1. Trulock E P., Christie J D., Edwards L B. et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007 26 782-795
2. Kim Y J., Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med 2007 28 222-242
3. Garbino J, Gerbase M W., Wunderli W et al. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact. Am J Respir Crit Care Med 2004 170 1197-1203
4. Milstone A P., Brumble L M., Barnes J et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006 28 131-137
5. Fan J, Henrickson K J., Savatski L L. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin Infect Dis 1998 26 1397-1402
6. Weinberg A, Zamora M R., Li S, Torres F, Hodges T N. The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol 2002 25 171-175
7. McCurdy L H., Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant 2003 22 745-753
8. Hopkins P, McNeil K, Kermeen F et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008 178 876-881
9. Falsey A R., Formica M A., Walsh E E. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol 2002 40 817-820
10. McIntosh K, McAdam A J. Human metapneumovirusan important new respiratory virus. N Engl J Med 2004 350 431-433
11. Vilchez R A., Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003 3 116-120
12. Mahalingam S, Schwarze J, Zaid A et al. Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections? Microbes Infect 2006 8 285-293
13. Kurt-Jones E A., Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000 1 398-401
14. Sha Q, Truong-Tran A Q., Plitt J R., Beck L A., Schleimer R P. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004 31 358-364
15. Delgado M F., Coviello S, Monsalvo A C. et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009 15 34-41
16. Graham B S., Rutigliano J A., Johnson T R. Respiratory syncytial virus immunobiology and pathogenesis. Virology 2002 297 1-7
17. Crowe J E. Jr, Williams J V. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev 2003 4 112-119
18. Castilow E M., Olson M R., Varga S M. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 2007 39 225-239
19. Olson M R., Varga S M. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol 2007 179 5415-5424
20. Tsitsikas D A., Oakervee H, Cavenagh J D., Gribben J, Agrawal S G., Mattes F M. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol 2009 146 574-576
21. Sparrelid E, Ljungman P, Ekelöf-Andström E et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997 19 905-908
22. Liu V, Dhillon G S., Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis 2009 Sep 15. [Epub ahead of print]
23. Pelaez A, Lyon G M., Force S D. et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009 28 67-71
24. Glanville A R., Scott A I., Morton J M. et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005 24 2114-2119
25. Nokes J D., Cane P A. New strategies for control of respiratory syncytial virus infection. Curr Opin Infect Dis 2008 21 639-643
26. Zhang W, Tripp R A. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol 2008 82 12221-12231
27. Garantziotis S, Howell D N., McAdams H P., Davis R D., Henshaw N G., Palmer S M. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 2001 119 1277-1280
28. Vilchez R, McCurry K, Dauber J et al. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation 2002 73 1075-1078
29. Hoft D F., Belshe R B. The genetic archaeology of influenza. N Engl J Med 2004 351 2550-2551
30. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009 58 893-896
31. Danziger-Isakov L A., Husain S, Mooney M L., Hannan M M., ISHLT Infectious Diseases Council. The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation. J Heart Lung Transplant 2009 28 1341-1347
32. Faix D J., Sherman S S., Waterman S H. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009 361 728-729
33. Le Goffic R, Pothlichet J, Vitour D et al. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol 2007 178 3368-3372
34. Mauad T, Hajjar L A., Callegari G D. et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010 181 72-79
35. McKinstry K K., Strutt T M., Buck A et al. IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol 2009 182 7353-7363
36. Sun J, Madan R, Karp C L., Braciale T J. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009 15 277-284
37. Vilchez R A., McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002 2 287-291
38. Kuo J H., Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA. J Pharm Pharmacol 2004 56 27-33
39. Vilchez R A., McCurry K, Dauber J et al. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis 2001 33 2004-2008
40. Moudgil A, Bagga A, Toyoda M, Nicolaidou E, Jordan S C., Ross D. Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Clin Transplant 1999 13 201-207
41. Winter J B., Gouw A S., Groen M, Wildevuur C, Prop J. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation 1994 57 418-422
42. Walter M J., Kajiwara N, Karanja P, Castro M, Holtzman M J. Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J Exp Med 2001 193 339-351
43. Hayney M S., Moran J, Wiegert N A., Burlingham W J. Lung transplant patients' T cell responses to influenza vaccine viruses between seasons. Vaccine 2008 26 2596-2600
44. Mazzone P J., Mossad S B., Mawhorter S D., Mehta A C., Schilz R J., Maurer J R. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 2001 18 971-976
45. Khazeni N, Bravata D M., Holty J E., Uyeki T M., Stave C D., Gould M K. Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009 151 464-473
46. Ison M G., Sharma A, Shepard J A., Wain J C., Ginns L C. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008 27 282-288
47. Khalifah A P., Hachem R R., Chakinala M M. et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004 170 181-187
48. Vilchez R A., Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connectionmyth or reality? Am J Transplant 2003 3 245-249
49. Cooper J D., Billingham M, Egan T et al, International Society for Heart and Lung Transplantation. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993 12 713-716
50. Kuo E, Bharat A, Goers T et al. Respiratory viral infection in obliterative airway disease after orthotopic tracheal transplantation. Ann Thorac Surg 2006 82 1043-1050
51. Welsh R M., Markees T G., Woda B A. et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol 2000 74 2210-2218
52. Rossini S, Casazza A P., Engelmann E C., Havaux M, Jennings R C., Soave C. Suppression of both ELIP1 and ELIP2 in Arabidopsis does not affect tolerance to photoinhibition and photooxidative stress. Plant Physiol 2006 141 1264-1273
53. Fishman J A., Rubin R H. Infection in organ-transplant recipients. N Engl J Med 1998 338 1741-1751
54. Taylor D O., Edwards L B., Boucek M M. et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report2007. J Heart Lung Transplant 2007 26 769-781
55. Manuel O, Kumar D, Moussa G et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009 87 719-725
56. Staras S A., Dollard S C., Radford K W., Flanders W D., Pass R F., Cannon M J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006 43 1143-1151
57. Gillespie G M., Wills M R., Appay V et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol 2000 74 8140-8150
58. Balthesen M, Messerle M, Reddehase M J. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993 67 5360-5366
59. Bonatti H, Tabarelli W, Ruttmann E et al. Impact of cytomegalovirus match on survival after cardiac and lung transplantation. Am Surg 2004 70 710-714
60. Soghikian M V., Valentine V G., Berry G J., Patel H R., Robbins R C., Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996 15 881-887
61. Duncan S R., Paradis I L., Yousem S A. et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992 146 1419-1425
62. Keenan R J., Lega M E., Dummer J S. et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991 51 433-438
63. Gandhi M K., Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004 4 725-738
64. Söderberg-Nauclör C, Fish K N., Nelson J A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997 91 119-126
65. Gold M C., Munks M W., Wagner M, Koszinowski U H., Hill A B., Fling S P. The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 T cell response in vivo. J Immunol 2002 169 359-365
66. Gerna G, Lilleri D, Rognoni V et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009 9 1142-1150
67. Weigt S S., Elashoff R M., Keane M P. et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant 2008 8 1512-1522
68. Shlobin O A., West E E., Lechtzin N et al. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 2006 176 2625-2634
69. Gamadia L E., Remmerswaal E B., Weel J F., Bemelman F, van Lier R A., Ten Berge I J. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 2003 101 2686-2692
70. Westall G P., Brooks A G., Kotsimbos T. CD8+ T-cell maturation following lung transplantation: the differential impact of CMV and acute rejection. Transpl Immunol 2007 18 186-192
71. Pipeling M R., West E E., Osborne C M. et al. Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol 2008 181 546-556
72. Kerschner H, Jaksch P, Karigl G, Popow-Kraupp T, Klepetko W, Puchhammer-Stöckl E. Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival. Transplantation 2009 87 1720-1726
73. Egan J J., Barber L, Lomax J et al. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax 1995 50 9-13
74. Guiver M, Fox A J., Mutton K, Mogulkoc N, Egan J. Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation 2001 71 1609-1615
75. Bhorade S M., Sandesara C, Garrity E R. et al. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant 2001 20 928-934
76. Weinberg A, Hodges T N., Li S, Cai G, Zamora M R. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000 38 768-772
77. Pang X L., Fox J D., Fenton J M., Miller G G., Caliendo A M., Preiksaitis J K., American Society of Transplantation Infectious Diseases Community of Practice Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009 9 258-268
78. Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 2006 82 (2, Suppl) S9-S14
79. Solans E P., Garrity E R. Jr, McCabe M, Martinez R, Husain A N. Early diagnosis of cytomegalovirus pneumonitis in lung transplant patients. Arch Pathol Lab Med 1995 119 33-35
80. Erice A, Hertz M I., Snyder L S., Englund J, Edelman C K., Balfour H H. Jr. Evaluation of centrifugation cultures of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis. Diagn Microbiol Infect Dis 1988 10 205-212
81. Chemaly R F., Yen-Lieberman B, Chapman J et al. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant 2005 5 544-548
82. Westall G P., Michaelides A, Williams T J., Snell G I., Kotsimbos T C. Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis 2004 190 1076-1083
83. Russo M J., Sternberg D I., Hong K N. et al. Postlung transplant survival is equivalent regardless of cytomegalovirus match status. Ann Thorac Surg 2007 84 1129-1134, discussion 11341135
84. Duncan S R., Grgurich W F., Iacono A T. et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994 150 146-152
85. Zamora M R. Cytomegalovirus and lung transplantation. Am J Transplant 2004 4 1219-1226
86. Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006 81 1415-1420
87. Chmiel C, Speich R, Hofer M et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008 46 831-839
88. Zamora M R., Nicolls M R., Hodges T N. et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004 4 1635-1642
89. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999 67 315-320
90. Jaksch P, Zweytick B, Kerschner H et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009 28 670-675
91. Limaye A P., Corey L, Koelle D M., Davis C L., Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000 356 645-649
92. Valantine H A., Luikart H, Doyle R et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001 72 1647-1652
93. Weill D, Lock B J., Wewers D L. et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 2003 3 492-496
94. Thomas L D., Milstone A P., Miller G G., Loyd J E., Stephen Dummer J. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Clin Transplant 2009 23 476-483
95. Monforte V, Romön A, Gavaldö J et al. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. Transplant Proc 2005 37 4039-4042
96. Limaye A P., Raghu G, Koelle D M., Ferrenberg J, Huang M L., Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002 185 20-27
97. Tamm M, Aboyoun C L., Chhajed P N., Rainer S, Malouf M A., Glanville A R. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004 170 1120-1123
98. Reddy A J., Zaas A K., Hanson K E., Palmer S M. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant 2007 26 1286-1292
99. Brestrich G, Zwinger S, Fischer A et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009 9 1679-1684
100. Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002 99 3916-3922
101. Brestrich G, Zwinger S, Roemhild A et al. Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. J Immunother 2009 32 932-940
102. Aris R M., Maia D M., Neuringer I P. et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naöve lung transplant recipient. Am J Respir Crit Care Med 1996 154 (6 Pt 1) 1712-1717
103. Tsai D E., Douglas L, Andreadis C et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008 8 1016-1024
104. Stevens S J., Verschuuren E A., Pronk I et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001 97 1165-1171
105. Knoop C, Kentos A, Remmelink M et al. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission. Clin Transplant 2006 20 179-187
106. Funch D P., Walker A M., Schneider G, Ziyadeh N J., Pescovitz M D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005 5 2894-2900
107. Deborska-Materkowska D, Lewandowski Z, Sadowska A et al. Fever, human herpesvirus-6 (HHV-6) seroconversion, and acute rejection episodes as a function of the initial seroprevalence for HHV-6 in renal transplant recipients. Transplant Proc 2006 38 139-143
108. Kidd I M., Clark D A., Sabin C A. et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000 69 2400-2404
109. Neurohr C, Huppmann P, Leuchte H et al, Munich Lung Transplant Group. Human herpesvirus 6 in bronchoalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005 5 2982-2991
110. Ross D J., Chan R C., Kubak B, Laks H, Nichols W S. Bronchiolitis obliterans with organizing pneumonia: possible association with human herpesvirus-7 infection after lung transplantation. Transplant Proc 2001 33 2603-2606
111. Christie J D., Edwards L B., Aurora P et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report2008. J Heart Lung Transplant 2008 27 957-969